Peptide-induced antiviral protection by cytotoxic T cells.
about
A multivalent vaccination strategy for the prevention of Old World arenavirus infection in humansUse of recombinant protein to identify a motif-negative human cytotoxic T-cell epitope presented by HLA-A2 in the hepatitis C virus NS3 regionEnhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positionsType 1 CD4(+) T-cell help is required for induction of antipeptide multispecific cytotoxic T lymphocytes by a lipopeptidic vaccine in rhesus macaquesDendritic cells efficiently induce protective antiviral immunity.Coverage of related pathogenic species by multivalent and cross-protective vaccine design: arenaviruses as a model systemInduction of cell-mediated immunity against Mycobacterium tuberculosis using DNA vaccines encoding cytotoxic and helper T-cell epitopes of the 38-kilodalton protein.Influenza virus-infected dendritic cells stimulate strong proliferative and cytolytic responses from human CD8+ T cells.Generation of cytotoxic and humoral immune responses by nonreplicative recombinant Semliki Forest virus.Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?Peptide-induced T-cell tolerance to prevent autoimmune diabetes in a transgenic mouse model.Induction of long-term memory CD8(+) T cells for recall of viral clearing responses against influenza virus.Induction of protective cytotoxic T cells to murine cytomegalovirus by using a nonapeptide and a human-compatible adjuvant (Montanide ISA 720).DNA vaccination against persistent viral infection.Neonatal DNA immunization with a plasmid encoding an internal viral protein is effective in the presence of maternal antibodies and protects against subsequent viral challenge.Antivirally protective cytotoxic T cell memory to lymphocytic choriomeningitis virus is governed by persisting antigen.Vaccination of rhesus monkeys with synthetic peptide in a fusogenic proteoliposome elicits simian immunodeficiency virus-specific CD8+ cytotoxic T lymphocytes.New dimensions in vaccinology: A new insight.T cell priming versus T cell tolerance induced by synthetic peptides.Resting memory CD8+ T cells are hyperreactive to antigenic challenge in vitro.Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lymphocyte responses.The next wave of recombinant and synthetic anticancer vaccines.Insertion signal sequence fused to minimal peptides elicits specific CD8+ T-cell responses and prolongs survival of thymoma-bearing mice.Mucosal herpes immunity and immunopathology to ocular and genital herpes simplex virus infections.A "string-of-beads" vaccine, comprising linked minigenes, confers protection from lethal-dose virus challenge.Hybrid human immunodeficiency virus Gag particles as an antigen carrier system: induction of cytotoxic T-cell and humoral responses by a Gag:V3 fusion.Induction of primary, antiviral cytotoxic, and proliferative responses with antigens administered via dendritic cellsSimian virus 40 T antigen as a carrier for the expression of cytotoxic T-lymphocyte recognition epitopes.Recombinant parvovirus-like particles as an antigen carrier: a novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells.Definition of a minimal optimal cytotoxic T-cell epitope within the hepatitis B virus nucleocapsid protein.Vaccination with a synthetic peptide modulates lymphocytic choriomeningitis virus-mediated immunopathologyDesign and development of synthetic peptide vaccines: past, present and future.Peptide-based vaccines for cancer: realizing their potential.Enhancing the recognition of tumour associated antigens.Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction.Targeting CD137 enhances vaccine-elicited anti-respiratory syncytial virus CD8+ T cell responses in aged mice.In vitro activity of CD4+ and CD8+ T lymphocytes from mice immunized with a synthetic malaria peptide.Priming of anti-human immunodeficiency virus (HIV) CD8+ cytotoxic T cells in vivo by carrier-free HIV synthetic peptides.Nonresponsiveness to an immunodominant Epstein-Barr virus-encoded cytotoxic T-lymphocyte epitope in nuclear antigen 3A: implications for vaccine strategiesT cell responses to viral infections - opportunities for Peptide vaccination.
P2860
Q24611383-94C1A086-A1ED-485F-B3F6-963C76607BF5Q27480326-37E959CC-41B6-4CA2-95D0-C8124593F787Q30448796-DED406BC-6EE5-4554-AA43-A90815C77352Q33648495-8095015B-A540-4F41-8452-230E8AA3EA74Q33782672-78351D1E-74EC-4983-8DE3-415D9C2BEB5DQ33909096-F2A1802D-6F6D-4AC0-BDFF-4802EF6706AFQ34008526-40497958-8008-4ED2-9C59-B7DE242B2572Q34229490-E6927392-6577-408B-A7F1-BDCE4658F801Q34527878-02457585-4698-4F63-8442-38BE1B6DCF51Q34669820-4DE0B9B4-6A12-4172-A4D0-C75FADAE36E2Q34975904-C593896D-FEDC-4AD1-A17C-A94605D76032Q34998462-90E4DB4D-4575-42CA-9BAA-F974A07BC61EQ35833323-9E62FFF5-AC88-4E1B-87B0-78F31E98D225Q35838136-E928D0CD-D0B1-4321-8FB5-CC32FB041724Q35896155-3B6F621C-2AD2-4619-BB26-2C3C7C6E2F9AQ36231954-0CDA2140-2872-43BC-8C3B-C6BCACC6EA5CQ36232166-8FB901A7-7266-4EEB-9965-26AD0B76228BQ36265802-3869A217-2A1F-4090-80F4-21D1EFC43D8EQ36365135-280729AE-B8D4-4C67-8273-62B76ECA0A03Q36377398-088DF7E5-3618-4276-B211-DAB30FCFCDA6Q36470715-A41D2EA8-3337-4E6C-987B-AE9C6DB36E7CQ36470749-51C55B2B-FF72-4567-B51A-90DFE09A7286Q36478934-F87B6796-4F24-43DD-BD5A-007781350146Q36520832-8109A841-B7C0-4BC7-AD2A-6D0867F60A49Q36639515-A6D22A96-624C-4E80-B642-0E152767B313Q36647277-CAFFBD6C-C1F1-4338-9581-AFB1ECBC566FQ36650065-0047ABCC-16CE-46C7-A3DC-82EFD9B272F3Q36654693-7376F8F3-AC76-45EC-8572-86532468786FQ36659320-12FAE591-26D0-4832-B415-0D93015634D3Q36687045-387385F1-FAC5-4113-85D2-F2DD9200C8C4Q36690788-3C5AEC02-463E-4C7E-9A5F-B5C05C1FAE25Q36899093-2538CF38-7CC6-404C-B0FD-23E13F299AA6Q37340462-99FE1634-23BA-450C-A501-A744A0AAA9F5Q37391100-E2F781C5-2CFF-4279-B4B7-66BE64D012C1Q37445352-0A59AF80-DDD7-4D5F-B0E7-EC2C6B6FE6BEQ37587807-A4A17B8F-B736-45FA-A944-FC6A79AFB62BQ37592267-ACACC208-C288-4C1B-AA32-5E64E06D7AB9Q37610962-706741E2-823F-448F-87FD-90C432B7971EQ37611115-9C62BD08-BFC1-4841-916D-4E9936BE6178Q37718978-20CB2569-9DA0-4371-BFAB-CDD74085A6CF
P2860
Peptide-induced antiviral protection by cytotoxic T cells.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 1991
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Peptide-induced antiviral protection by cytotoxic T cells.
@en
Peptide-induced antiviral protection by cytotoxic T cells.
@nl
type
label
Peptide-induced antiviral protection by cytotoxic T cells.
@en
Peptide-induced antiviral protection by cytotoxic T cells.
@nl
prefLabel
Peptide-induced antiviral protection by cytotoxic T cells.
@en
Peptide-induced antiviral protection by cytotoxic T cells.
@nl
P2093
P2860
P356
P1476
Peptide-induced antiviral protection by cytotoxic T cells.
@en
P2093
Hengartner H
Zinkernagel RM
P2860
P304
P356
10.1073/PNAS.88.3.991
P407
P577
1991-02-01T00:00:00Z